未登录

M

Mattis Flyvholm Ranthe

novonordisk

H指数:16

被引数:1,219

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin

DIABETIC MEDICINE

IF3.4

2019-11-286

OAAI

Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trial

DIABETES OBESITY & METABOLISM

IF5.7

2019-09-1719

OAAI

IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy

DIABETES OBESITY & METABOLISM

IF5.7

2019-08-2810

OAAI

Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naive Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial

DIABETES OBESITY & METABOLISM

IF5.7

2019-08-2816

OAAI

IDegLira Improves Glycemic Control in Japanese Patients with Type 2 Diabetes (T2D) Uncontrolled on Premixed Insulin Therapy

IF7.5

2019-06-011

PRE

Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10)

DIABETES OBESITY & METABOLISM

IF5.7

2019-04-018

OAAI

Co-occurrence of infantile hypertrophic pyloric stenosis and congenital heart defects: a nationwide cohort study

PEDIATRIC RESEARCH

IF3.1

2019-03-123

OAAI

Rare truncating variants in the sarcomeric protein titin associate with familial and early-onset atrial fibrillation

NATURE COMMUNICATIONS

IF15.7

2018-10-1795

OAAI

Rates of Major Adverse Cardiovascular (CV) Events (MACE) and Mortality with Basal Insulin by Liraglutide Use-A DEVOTE Subanalysis

IF7.5

2018-07-011

PRE

Use of Big-Data Algorithms to Characterize Patients with T2D on Basal Insulin (BI) Who Add a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) and Predict Their A1C Response

IF7.5

2018-07-010

PRE

Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial

在双V随机试验中，胰岛素degludec/利拉鲁肽 (IDegLira) 在一系列血糖异常和体重指数类别中有效

DIABETES OBESITY & METABOLISM

IF5.7

2017-07-3113

OAAI

Association Between Hypertensive Disorders of Pregnancy and Later Risk of Cardiomyopathy EDITORIAL COMMENT

OBSTETRICAL & GYNECOLOGICAL SURVEY

IF3.6

2016-07-010

PREAI

Association Between Hypertensive Disorders of Pregnancy and Later Risk of Cardiomyopathy

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

IF55

2016-03-08104

OAAI

Association between pregnancy losses in women and risk of atherosclerotic disease in their relatives: a nationwide cohort study

EUROPEAN HEART JOURNAL

IF35.6

2015-10-2412

OAAI

Miscarriage and cardiovascular disease

IF4.4

2015-09-186

PREAI

Risk of Cardiomyopathy in Younger Persons With a Family History of Death from Cardiomyopathy A Nationwide Family Study in a Cohort of 3.9 Million Persons

有心肌病死亡家族史的年轻人患心肌病的风险一项针对3.9万人的全国性家庭研究

IF38.6

2015-09-1521

OAAI

Atypical Antipsychotics Olanzapine, Quetiapine, and Risperidone and Risk of Acute Major Cardiovascular Events in Young and Middle-Aged Adults: A Nationwide Register-Based Cohort Study in Denmark

IF7.4

2014-06-0411

PREAI

Cardiac involvement in myotonic dystrophy: a nationwide cohort study

强直性肌营养不良症的心脏受累: 一项全国性队列研究

EUROPEAN HEART JOURNAL

IF35.6

2014-04-1643

OAAI

Pregnancy Loss and Later Risk of Atherosclerotic Disease

IF38.6

2013-04-3087

OAAI

Risk of cardiovascular disease in family members of young sudden cardiac death victims

EUROPEAN HEART JOURNAL

IF35.6

2012-11-1353

OAAI